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Abstract
Haptoglobin’s (Hp) antioxidant and pro-angiogenic properties differ between the 1-1, 2-1, and 2-2 phenotypes. Hp
phenotype affects cardiovascular disease risk and treatment response to antioxidant vitamins in some non-pregnant
populations. We previously demonstrated that preeclampsia risk was doubled in white Hp 2-1 women, compared to Hp 1-1
women. Our objectives were to determine whether we could reproduce this finding in a larger cohort, and to determine
whether Hp phenotype influences lack of efficacy of antioxidant vitamins in preventing preeclampsia and serious
complications of pregnancy-associated hypertension (PAH). This is a secondary analysis of a randomized controlled trial in
which 10,154 low-risk women received daily vitamin C and E, or placebo, from 9-16 weeks gestation until delivery. Hp
phenotype was determined in the study prediction cohort (n = 2,393) and a case-control cohort (703 cases, 1,406 controls).
The primary outcome was severe PAH, or mild or severe PAH with elevated liver enzymes, elevated serum creatinine,
thrombocytopenia, eclampsia, fetal growth restriction, medically indicated preterm birth or perinatal death. Preeclampsia
was a secondary outcome. Odds ratios were estimated by logistic regression. Sampling weights were used to reduce bias
from an overrepresentation of women with preeclampsia or the primary outcome. There was no relationship between Hp
phenotype and the primary outcome or preeclampsia in Hispanic, white/other or black women. Vitamin supplementation
did not reduce the risk of the primary outcome or preeclampsia in women of any phenotype. Supplementation increased
preeclampsia risk (odds ratio 3.30; 95% confidence interval 1.61–6.82, p,0.01) in Hispanic Hp 2-2 women. Hp phenotype
does not influence preeclampsia risk, or identify a subset of women who may benefit from vitamin C and E supplementation
to prevent preeclampsia.
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Introduction
Preeclampsia affects 2–7% of pregnancies [1,2]. Diagnosed as
new onset hypertension and proteinuria after 20 weeks gestation
[1,2], preeclampsia is a leading cause of maternal [3] and fetal [4]
morbidity and mortality. Oxidative stress (including low antiox-
idant levels) and angiogenic imbalance are believed to contribute
to preeclampsia [5,6,7]. No intervention has been proven to
prevent preeclampsia. Vitamin C and E lowered preeclampsia
incidence by 60% in a pilot randomized controlled trial (RCT) in
high-risk women [8]. Unfortunately, this effect was not confirmed
in subsequent RCTs involving high [9,10,11,12,13] or low-risk
women [13,14,15]. Although the discordant effects in large and
small populations are likely due to reduced power in small studies,
differences might also be explained by increased heterogeneity in
large multicenter studies obscuring a responsive subset of women.
The phenotype of the antioxidant [16] and pro-angiogenic [17]
protein haptoglobin (Hp) predicts cardiovascular disease risk, and
responsiveness to Vitamin E [18,19,20] or C and E [21] in some
non-pregnant populations. We examined whether Hp phenotype
might influence preeclampsia risk, or identify a subset of women
who responded to vitamin supplementation. Hp stimulates
angiogenesis [17] and acts as a powerful antioxidant by clearing
free hemoglobin following hemolysis [16]. Hp’s two different a
alleles (a1, a2) give rise to three genetically determined phenotypes
(1-1, 2-1 and 2-2) [16]. Size and structural differences (Figure 1)
lead to functional differences between phenotypes [16]. Hp 1-1 is a
stronger antioxidant [16], whereas Hp 2-2 is more angiogenic
[17]. Less is known about the function of Hp 2-1, a highly variable
heterodimer which is not commercially available. Hp 2-1
individuals have no Hp 2-2, very little Hp 1-1, and large amounts
of the 2-1 forms which are structurally very different from Hp 1-1
or 2-2 [16].
We chose to examine Hp phenotype and preeclampsia for three
reasons. First, Hp’s antioxidant and pro-angiogenic properties
depend on phenotype [17,22,23]. Oxidative stress and reduced
angiogenesis contribute to preeclampsia [5,6]. In our recent case-
control study, Hp 2-1 was associated with increased preeclampsia
risk in non-hispanic white women, but not in black women [24].
We sought to confirm these findings in a larger cohort while
extending the existing literature to include Hispanics. Second, any
potential effect of Hp phenotype on preeclampsia risk or treatment
response would affect a significant number of women. Hp 1-1, 2-1
and 2-2 are all common in whites, blacks and Hispanics
(prevalences of 16%-50%) [25]. Third, Hp phenotype predicts
cardiovascular disease risk, and responsiveness to Vitamin E
[18,19,20] or C and E [21] in other non-pregnant populations. Hp
2-2 diabetics are twice as likely to have a cardiovascular event as
Hp 1-1 and 2-1 diabetics [18,21,26]. Vitamin E supplementation
eliminates this increased risk in Hp 2-2 diabetics, but has no effect
in Hp 1-1 or 2-1 diabetics [18,19,27]. In contrast, Vitamin C may
be harmful in Hp 2-2 diabetics as oxidation of Vitamin C may
exacerbate pre-existing oxidative stress [28]. In post-menopausal
women with coronary artery disease, Vitamin C and E decreased
coronary artery diameter in Hp 2-2 diabetic women [21]. This
harmful effect was not universal, as Vitamin C and E benefited Hp
1-1 women by significantly increasing coronary artery diameter
[21].
We sought to determine whether Hp phenotype was associated
with serious complications of pregnancy-associated hypertension
(PAH) or preeclampsia in white, black or Hispanic women. We
also examined whether Hp phenotype might influence respon-
siveness to antioxidant vitamins in preventing preeclampsia. Based
on our previous findings, we hypothesized that Hp 2-1 would be
associated with increased preeclampsia risk in white women, but
not in black women. We also posited that phenotype would affect
treatment response although directionality was difficult to predict
based upon data from non-pregnant populations.
Materials and Methods
Population
This was a secondary analysis of a Eunice Kennedy Shriver National
Institute of Child Health and Human Development Maternal-
Figure 1. Hp phenotypes by Native and SDS PAGE. Panel A: Hp phenotyping of Hb-supplemented serum by Native PAGE on a 6% gel. Hp 2-2
(Lane 1) is a heterodimer with a series of slow moving bands. Hp 1-1 (Lane 4) is a homodimer with one fast moving band. Hp 2-1 (Lanes 2, 3, 5) has a
band between the Hb/Hp 1-1 and Hb/Hp 2-2 bands, and several slow-moving bands in the same region as the Hb/Hp 2-2 bands. Panel B: In the rare
Hp 2-1 M phenotype, a modification of the Hp a2 allele leads to overproduction of the fast migrating Hp 1-1 band, relative to the slower migrating
Hp 2-1 bands. This results in a stronger Hb/Hp 1-1 band, and weaker Hb/Hp 2-1 bands, than in Hp 2-1. Panel C: Hp phenotyping of serum by SDS
PAGE on a 12% gel. The Hp b band is common to all phenotyes. The presence of the Hp 1 and 2 alleles is indicated by the a1 and a2 bands,
respectively.
doi:10.1371/journal.pone.0060479.g001
Haptoglobin Phenotype, Vitamins and Preeclampsia
PLOS ONE | www.plosone.org 2 April 2013 | Volume 8 | Issue 4 | e60479
Fetal Medicine Units Network double-blind, multicenter RCT
(NCT 00135707) in which 10,154 nulliparous, low risk women
received daily doses of 400 IU of vitamin E and 1000 mg of
vitamin C, or placebo, from 9-16 weeks gestation until delivery.
The trial was conducted at 16 centers in the US between 2003 and
2008. Full details of the study were reported previously [14]. The
trial was conducted in accordance with the Declaration of Helsinki
of the World Medical Association. All subjects provided written,
informed consent before participating. Hp phenotyping was
performed at the University of Pittsburgh (Institutional Review
Board approval PRO10010368).
Outcomes
The primary outcome was severe PAH, or mild or severe PAH
with elevated liver enzymes (aspartate aminotransferase $100 U
per liter), elevated serum creatinine ($1.5 mg/dl), thrombocyto-
penia (,100,000 platelets/mm3), eclampsia, fetal growth restric-
tion (,3rd centile adjusted for sex and race/ethnicity), medically
indicated preterm birth before 32 weeks due to PAH, or fetal
death after 20 weeks gestation, or neonatal death. Hypertension
was diagnosed using blood pressure measurements obtained
during or after 20 weeks gestation, excluding intraoperative and
intrapartum systolic blood pressures. Severe PAH was defined as a
systolic blood pressure of 160 mm Hg or more, or a diastolic blood
pressure of 110 mm Hg or more on two occasions 2 to 240 hours
apart, or a single severely elevated blood pressure measurement
that led to treatment with antihypertensive medication. Mild PAH
was defined as systolic pressure between 140 and 159 mm Hg or a
diastolic pressure between 90 mm Hg and 109 mm Hg on two
occasions 2 to 240 hours apart. Mild preeclampsia was defined as
mild PAH with proteinuria documented within the 3 days
preceding or following the elevated blood pressure measurement.
Proteinuria was defined as protein excretion $300 mg/24 hours,
a dipstick urinary protein $2+, or protein:creatinine $0.35 in the
absence of a 24-hour urine sample. Early onset preeclampsia was
defined as preeclampsia requiring delivery before 37 weeks
gestation. Severe preeclampsia was defined as preeclampsia with
either severe PAH or protein excretion 35 g/24 hours, or as mild
PAH with oliguria (,500 ml urine/24 hours), pulmonary edema
(confirmed by radiography), or thrombocytopenia (,100,000
platelets/mm3).
Design
The RCT included 10,154 women, of whom 2,434 were
enrolled in a nested prediction cohort. The RCT design specified
that secondary analyses requiring blood be conducted in the
prediction cohort, as these women consented to extra blood
collection for prediction and pathophysiology studies. If additional
subjects were required, investigators could obtain samples from the
7,720 women not in the prediction cohort, in whom very little
blood was collected. We needed samples from all white, black, and
Hispanic women with preeclampsia in the RCT to detect a 2-fold
increase in preeclampsia risk in Hp 2-1, compared to Hp 1-1, in
each racial group (a=0.05; Power: 83% white, 96% black, 98%
Hispanic). We determined Hp phenotype in the prediction cohort;
then added a case-control cohort composed of women who were
not in the prediction cohort. The case-control cohort allowed us to
capture all cases without phenotyping 5,500 additional controls.
Cases in the case-control cohort included all women with
preeclampsia, the primary outcome, or both (n= 703 cases) who
were not in the prediction cohort. We selected 2 controls per case
(n = 1,406) [29], matched for center and race/ethnicity (Figure 2).
Hp Phenotyping
Hp phenotyping was performed as described previously [24,30].
Serum samples (5 ml) supplemented with human hemoglobin
(Sigma-Aldrich, St. Louis, MO) were phenotyped by hemoglobin-
Hp complex peroxidase activity on native polyacrylamide gel
electrophoresis (PAGE). Hemolyzed samples and samples with low
Hp concentrations were phenotyped by Western blot following
sodium dodecyl sulfate (SDS) PAGE of 1 to 6 ml of serum. Proteins
from native and SDS gels were transferred to a polyvinylidene
fluoride (PVDF) membrane (Millipore, Billerica, MA). SDS PAGE
was followed by Western blotting with primary (1:5,000,
Polyclonal Rabbit Anti-Human Haptoglobin, DakoCytomation,
Carpinteria, CA) and secondary (1:25,000, Goat anti-Rabbit IgG
horseradish peroxidase, Millipore) antibodies. Membranes were
stained for peroxidase activity (SuperSignal West Pico Chemilu-
minescent Substrate, Fisher Scientific, Pittsburgh, PA) and imaged
(FlouroChem Q System, Cell Biosciences, Santa Clara, CA). Hp
phenotypes were identified by banding patterns of the Hp-
hemoglobin complexes (native PAGE, Figure 1) or the Hp a1 and
a2 alleles (SDS PAGE).
Plasma Ascorbate
Blood was collected in vials containing metaphosphoric acid,
and frozen at 280 C [31]. Plasma ascorbic acid was measured by
high performance liquid chromatography in the Molecular
Epidemiology and Biomarker Laboratory (University of Minne-
sota) as described previously [31].
Statistical Analysis
The prediction and case-control cohorts were analyzed sepa-
rately (statistical methods in Data S1); then pooled to maximize
power. In the pooled analysis, sampling weights were applied to
reduce potential bias arising from an overrepresentation of women
with the primary outcome (but not preeclampsia) in the control
group for preeclampsia analyses, and an oversampling of women
with preeclampsia (but not the primary outcome) in the control
group for primary outcome analyses. Patients from the prediction
cohort were assigned a weight of one. Cases and controls were
assigned a sample weight defined as the inverse of their probability
of selection [32]. Sample weights included a post-stratification
adjustment for race/ethnicity. Baseline characteristics were
compared using the t-test for continuous variables and the Rao-
Scott chi-square test [33] for categorical variables. Logistic
regression models were constructed to assess the multivariable
association between Hp phenotype and the incidence of each
outcome, adjusting for variables that were associated with Hp
phenotype in univariate analyses. Odds ratios and 95% confidence
intervals were estimated from unconditional survey logistic
regression models. Taylor series replicate weights were created
to estimate standard errors and p values in the weighted analyses.
Model covariates included randomization group, and demograph-
ic variables that differed between women with the Hp 1-1, 2-1 and
2-2 phenotypes (age, self-reported vitamin use, education level,
diastolic blood pressure at screening). The weighted analysis gave
similar results to an unweighted analysis (i.e. samples were not
weighted by the post-stratification sample weights; data not
shown). Results were considered to be statistically significant at
a=0.05 with no adjustment for multiple comparisons [34]. All p
values are 2-sided. SAS Version 9.2 (SAS Institute Inc.) and
STATA (StataCorp, 2011 Stata Statistical Software: Release 12,
College Station, TX, StataCorp LP), using procedures appropriate
for sample-weighted data, were used for all analyses.
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Results
Cohorts
We phenotyped 2,393 of the 2,434 women in the prediction
cohort (Figure 2), excluding 40 women who miscarried, and one
who had no samples collected. The case-control cohort included
all remaining subjects who developed the primary outcome only
(severe PAH, or mild or severe PAH with elevated liver enzymes,
elevated serum creatinine, thrombocytopenia, eclampsia, fetal
growth restriction, medically indicated preterm birth or perinatal
death) (n = 190), preeclampsia only (n = 280), or the primary
outcome and preeclampsia (n = 233), and 1,406 controls matched
for center and race/ethnicity. Women in the prediction cohort
entered the study at an earlier gestational age (11.461.1) than
women in the case-control cohort (14.062.0). Results of separate
analyses for the prediction (Data S1; Tables S1, S2) and case-
control cohorts (Data S1; Tables S3, S4, S5, S6, S7) are presented
in Data S1. Results for the pooled cohort are described below.
Subjects
The pooled dataset included 1,008 Hp 1-1, 2,129 Hp 2-1 and
1,261 Hp 2-2 women. Ninety-six women had the rare 2-1 M
phenotype, which results from a modification of the a2 allele [16].
These women were excluded from subsequent analyses. There
were 1,840 white women, 1,392 black women, 1,188 Hispanic
women, and 74 women of ‘‘Other’’ race.
Weighting
The weighted sample included 2,201 Hp 1-1 women, 4,840 Hp
2-1 women, 2,760 Hp 2-2 women, and 146 Hp 2-1 M women.
The weighted cohort accurately reproduced the demographic
characteristics of the original sample (Table S8). Demographic
characteristics in the weighted cohort were not significantly
different between the placebo and vitamin groups.
Subject Characteristics
As expected, race/ethnicity differed between women with the
Hp 1-1, 2-1, 2-2 and 2-1 M phenotypes (Table 1). The phenotype
distribution for each race/ethnicity was similar to previous reports
(Table 1, S9) [25]. Hp phenotype groups did not differ with
respect to pre-pregnancy BMI, blood pressure at randomization,
smoking, history of a previous pregnancy, or family history of
preeclampsia (Table 1). Subsequent analyses were adjusted for
characteristics that differed between the Hp 1-1, 2-1 and 2-2
groups (race/ethnicity, age, education, vitamin use). Analyses were
also adjusted for diastolic blood pressure at randomization, which
differed between phenotype groups in the prediction cohort (Table
S10) but not in the pooled cohort. The white and other groups
were pooled for race/ethnicity adjustments, as phenotype preva-
lence in the other group was most similar to whites (Table S9).
Primary Outcome and Preeclampsia Risk
Hp phenotype was not significantly associated with the risk of
the primary outcome, preeclampsia, severe preeclampsia, or early
onset preeclampsia in white/other, Hispanic or black women
(Table 2). Women of ‘‘other’’ race comprised 4% of the white/
other group, and results were not different when these women
were excluded (data not shown). The relationship between Hp
phenotype on early onset preeclampsia approached statistical
significance (p = 0.06) in Hispanics.
Treatment Response
Vitamin C and E supplementation did not prevent the primary
outcome or any form of preeclampsia among white/other, black
or Hispanic women of any Hp phenotype after adjusting for
vitamin use, age, education, and diastolic blood pressure at
randomization (data not shown).
In Hispanics, the effect of vitamin supplementation differed
between Hp phenotype groups for preeclampsia (Hp phenotype*-
treatment group: p,0.01) and late onset preeclampsia (p = 0.02),
Figure 2. Study Flow Chart. Subjects lost to follow-up include 183 women who miscarried, one subject whose data were removed at the patient’s
request, and one subject whose data were removed at the institutional review board’s request.
doi:10.1371/journal.pone.0060479.g002
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Table 1. Subject Characteristics for the Weighted Pooled Cohort by Hp phenotype.
Subject Characteristics Hp 1-1 (n =2,201) Hp 2-1 (n=4,840) Hp 2-2 (n=2,760) Hp 2-1 M (n=161) p
Age – years 22.464.9 23.665.1* 24.065.1* 20.263.7*,{,` ,0.01
Gestational age at randomization – week 13.462.1 13.362.0 13.462.1 13.062.5 0.48
Race or ethnicity - % within phenotype NA
White 618 (28%) 2,142 (44%) 1,408 (51%) 3 (2%)
Black 779 (35%) 1,059 (22%) 542 (20%) 132 (82%)
Hispanic 779 (35%) 1,555 (32%) 724 (26%) 25 (6%)
Other 25 (1%) 84 (2%) 86 (3%) 1 (,1%)
Pre-pregnancy body mass index - kg/m2 25.366.1 24.965.4 25.065.6 26.668.7 0.20
Smoked during pregnancy – n (%) 352 (16%) 721 (15%) 515 (19%) 23 (15%) 0.12
Education - years 12.262.9 12.762.7* 13.162.6*,{ 12.062.0{,` ,0.01
Prenatal/multivitamin use prior to randomization – n (%) 1,517 (69%) 3,759 (78%)* 2,194 (79%)* 132 (82%)* ,0.01
Previous pregnancy – n (%) 520 (24%) 1,084 (22%) 731 (26%) 33 (21%) 0.16
Family history of preeclampsia – n (%) 319 (14%) 634 (13%) 341 (12%) 18 (11%) 0.64
Blood pressure at entry (9-12 weeks)
Systolic – mm Hg 108610 108610 108610 11069 0.23
Diastolic – mm Hg 6568 6568 6568 6469 0.25
Values are mean6 SD or n (%). Abbreviations: NA; not applicable. Statistical comparisons for race/ethnicity were not performed, as cases and controls were matched for
race/ethnicity.
Significant difference (p,0.05) from: *Hp 1-1, {Hp 2-1, `Hp 2-2.
doi:10.1371/journal.pone.0060479.t001
Table 2. Outcomes according to race/ethnicity and Hp phenotype in the weighted pooled cohort.
Outcome Weighted Cases (n) Hp 2-1{ OR (95% CI) Hp 2-2{ OR (95% CI)
White/Other
Primary Outcome* 216 0.87 (0.56, 1.35) 0.92 (0.58, 1.45)
Preeclampsia 222 0.98 (0.62, 1.54) 1.18 (0.74, 1.88)
Severe Preeclampsia 90 1.30 (0.65, 2.62) 1.31 (0.64, 2.69)
Early Onset Preeclampsia 58 0.96 (0.41, 2.22) 1.40 (0.61, 3.22)
Late Onset Preeclampsia 163 0.98 (0.59, 1.64) 1.10 (0.65, 1.87)
Black
Primary Outcome 243 1.26 (0.90, 1.76) 1.00 (0.66, 1.51)
Preeclampsia 237 1.03 (0.74, 1.45) 0.92 (0.61, 1.38)
Severe Preeclampsia 115 1.14 (0.73, 1.80) 0.88 (0.49, 1.55)
Early Onset Preeclampsia 74 1.18 (0.67, 2.07) 0.95 (0.48, 1.88)
Late Onset Preeclampsia 163 0.97 (0.66, 1.44) 0.90 (0.56, 1.46)
Hispanic
Primary Outcome 116 0.79 (0.49, 1.29) 0.85 (0.47, 1.54)
Preeclampsia 217 0.77 (0.53, 1.12) 0.74 (0.46, 1.19)
Severe Preeclampsia 76 0.71 (0.40, 1.24) 0.67 (0.32, 1.40)
Early Onset Preeclampsia 42 0.41 (0.20, 0.86) 0.53 (0.21, 1.37)
Late Onset Preeclampsia 175 0.90 (0.60, 1.37) 0.82 (0.49, 1.39)
Hp 1-1 was the reference group for odds ratios. Hp phenotype was determined in 1,573 black women, 1,164 Hispanic women, and 1,432 women of white or other race.
Each observation was weighted to reflect the pregnancy outcomes and racial distribution of the full cohort.
*The primary outcome was severe PAH, or mild or severe PAH with elevated liver enzymes, elevated serum creatinine, thrombocytopenia, eclampsia, fetal growth
restriction, medically indicated preterm birth or perinatal death.
Abbreviations: OR, odds ratio; CI, confidence interval.
{Adjusted for group (treatment vs. placebo), race/ethnicity, age, education, vitamin use and diastolic blood pressure at randomization.
doi:10.1371/journal.pone.0060479.t002
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but not for severe (p = 0.06) or early onset preeclampsia (p = 0.10).
Vitamin supplementation significantly increased preeclampsia
(odds ratio (OR) 3.30; 95% confidence interval (CI) 1.61-6.82,
p,0.01, Table 3) and late onset preeclampsia risk (3.01; 1.38-6.57,
p,0.01) in Hispanic Hp 2-2 women. This adverse effect was not
seen in Hp 1-1 or 2-1 Hispanics (p.0.05), or in white/other or
black women of any phenotype.
Increased preeclampsia risk in Hispanic Hp 2-2 women was
specific to the large quantities of vitamins C and E in study
supplements. Prenatal/multivitamin use at randomization was not
associated with an increased risk of preeclampsia (2.17; 0.53-8.71,
p = 0.27) or late onset preeclampsia (2.85; 0.57–14.36, p = 0.20) in
Hispanic Hp 2-2 women receiving placebo. Low rates of prenatal/
multivitamin use at randomization (43% in Hispanics vs. 91% in
non-Hispanics, Table S10) are unlikely to explain why the adverse
effect of supplementation in Hp 2-2 women was only seen in
Hispanics. Hispanic 2-2 women who were not taking prenatal
vitamins at randomization had a smaller increase in preeclampsia
risk with supplementation than Hispanic 2-2 women who were
taking prenatal vitamins at randomization (2.01; 0.80–5.01,
p = 0.14 vs. 7.83; 2.01–30.53, p,0.01, Table 4).
Hp Phenotype, Prenatal/Multivitamin Use at
Randomization, and Plasma Ascorbate
Hp phenotype influences plasma ascorbate concentration [35],
providing a potential mechanism by which Hp phenotype might
influence treatment response to vitamin C and E. We examined
the relationship between Hp phenotype and plasma ascorbate in a
pre-planned analysis. Plasma ascorbate was measured at the pre-
randomization screening visit in 264 women with known Hp
phenotypes. Plasma ascorbate was lower in women who were not
taking a prenatal/multivitamin at randomization (n = 34) com-
pared to those who were (n = 230) (p = 0.02 for main effect,
Table 5). Statistical comparisons within phenotype groups were
not conducted, as the number of women who were not taking
prenatal/multivitamins at randomization within each phenotype
group was very small. Hp phenotype was not significantly
associated with plasma ascorbate (p = 0.73). The interaction
between Hp phenotype and vitamin use at randomization was
not significant (p = 0.32). Plasma ascorbate was only measured in
six Hispanic Hp 2-2 women; therefore we could not determine
whether supplementation had a different effect on plasma
ascorbate in this group.
Discussion
Hp phenotype was not associated with the risk of the primary
outcome (a composite of PAH and serious adverse outcomes in the
mother, her fetus or neonate) or any type of preeclampsia in white,
black or Hispanic women. Moreover, daily vitamin C and E
supplementation did not prevent the primary outcome or
preeclampsia in women of any Hp phenotype. Supplementation
increased the risk of preeclampsia and late onset preeclampsia by
3-fold in Hispanic Hp 2-2 women.
Hp Phenotype and the Risk of Preeclampsia and Serious
Complications of PAH
We found no relationship between Hp phenotype and the
primary outcome or preeclampsia risk in white, black or Hispanic
women. This study has two key strengths. First, it extends the
existing literature by including large numbers of black and
Hispanic women. Previous studies focused on predominantly
white, non-Hispanic women [24,36,37,38]. Studies examining the
relationship between Hp phenotype and preeclampsia risk in
different racial groups were recently recommended [39]. Second,
this is the largest study of non-Hispanic white women completed to
date, and was adequately powered to detect the difference that we
observed in our previous case-control study [24]. This is
particularly important, as the heterogeneous results and small
sample sizes of previous European studies suggests that spurious
findings may be common. At the time we initiated this
investigation, two small, underpowered European studies had
reported that preeclampsia risk was not different [38] or increased
[36] in Hp 1-1 white women. Adequately powered studies [39],
and studies in North American women, were needed. An Israeli
study subsequently reported a 50% reduction in preeclampsia risk
among Hp 1-1 women, compared to Hp 2-1 and 2-2 [24,30,37].
Our larger case-control study suggested that Hp 1-1 was only
protective when compared to Hp 2-1, and not Hp 2-2 [24].
Unfortunately, we were unable to confirm this finding in the
present cohort. However, we did confirm our previous preliminary
data [24] suggesting that there was no relationship between Hp
phenotype and preeclampsia risk in black women in a large
adequately powered cohort. The trend (p= 0.06) towards an
increased risk of early onset preeclampsia in Hp 2-1 and 2-2
Table 3. Odds ratios for effect of treatment in Hispanic
women in the weighted pooled cohort.
Outcome Phenotype OR (95% CI)* p*
Preeclampsia Hp 1-1 0.71 (0.39, 1.29) 0.27
Hp 2-1 0.95 (0.61, 1.50) 0.83
Hp 2-2 3.30 (1.61, 6.82) ,0.01
Late Onset Preeclampsia Hp 1-1 0.70 (0.36, 1.35) 0.29
Hp 2-1 1.02 (0.63, 1.66) 0.92
Hp 2-2 3.01 (1.38, 6.57) ,0.01
*Adjusted for vitamin use, age, education and diastolic blood pressure at
randomization.
doi:10.1371/journal.pone.0060479.t003
Table 4. Odds ratios for treatment effect in Hispanic Hp 2-2 women according to prenatal/multivitamin use at randomization.
Outcome Vitamin Use at Randomization OR (95% CI)* p*
Preeclampsia Yes 7.83 (2.01, 30.53) ,0.01
No 2.01 (0.80, 5.01) 0.14
Late Onset Preeclampsia Yes 8.23 (1.64, 41.28) 0.01
No 1.91 (0.73, 5.00) 0.18
*Adjusted for age, education and diastolic blood pressure at randomization.
doi:10.1371/journal.pone.0060479.t004
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Hispanics was likely a spurious result due to the small number of
cases (n = 42).
Hp Phenotype and Vitamin C and E
Accumulating evidence suggests that preeclampsia and later life
cardiovascular disease are intimately linked. These conditions
share several risk factors (i.e. black race, obesity, diabetes) and
pathophysiological processes (inflammation, oxidative stress, en-
dothelial dysfunction, and impaired angiogenesis) [40,41]. The
American Heart Association recently recognized preeclampsia as a
cardiovascular disease risk factor [41]. Hp phenotype affects
cardiovascular disease risk and treatment response to antioxidant
vitamins in some non-pregnant populations, particularly in
diabetics [18,19,21,26]. Uncomplicated pregnancy is an insulin
resistant state [42], and gestational diabetes [43] and Type 1
diabetes [44] increase preeclampsia risk. Therefore, we examined
the potential for Hp phenotype to influence the effectiveness of
vitamin C and E in preventing preeclampsia and serious
complications of PAH.
Daily vitamin C and E did not prevent preeclampsia or serious
complications of PAH in low risk primiparous women of any Hp
phenotype. Supplementation actually increased preeclampsia risk
by 3-fold in Hispanic Hp 2-2 women, however the mechanism
requires further investigation. This effect was not explained by the
strikingly lower prevalence of vitamin supplementation at
randomization in Hispanics. Hispanic women have an increased
risk of the metabolic syndrome and diabetes, conditions associated
with oxidative stress [45]. Platelet volume, a marker of accelerated
platelet turn over, was increased in Hispanic women compared to
white or black women in the prediction cohort [46]. Accelerated
platelet turnover could indicate low-grade intravascular coagula-
tion and subsequent mild chronic hemolysis. The resulting
oxidative stress would be worse in Hp 2-2 women due to the
low antioxidant capacity of this phenotype. We speculate that
supplementation may have exacerbated pre-existing oxidative
stress, and therefore preeclampsia risk, in Hispanic Hp 2-2 women
by increasing ascorbate radical formation. A definitive explanation
will be sought in future studies. Supplementation increased the risk
of late onset preeclampsia, but not early onset preeclampsia, in Hp
2-2 Hispanics. This could reflect pathophysiological differences
between these conditions or lower power due to fewer cases of
early onset preeclampsia.
Several factors could explain the difference between our results
and previous research in other populations [18,19,21,26]. First,
cardiovascular disease studies suggest that vitamin E alone has
different effects from vitamin C and E combined [18,19,27].
Vitamin C and E can be beneficial or harmful, depending on Hp
phenotype [27]. Coronary artery diameter increased following
vitamin C and E supplementation in Hp 1-1 post-menopausal
women with coronary artery disease. However, the pro-oxidant
effects of vitamin C [28] combined with the reduced antioxidant
capacity of Hp 2-2 may have contributed to accelerated coronary
artery narrowing in diabetic Hp 2-2 post-menopausal women
taking vitamins C and E [21]. Oxidative stress increases in
pregnancy [40], suggesting that a similar mechanism could be
active in Hp 2-2 pregnant women. In partial support of this
hypothesis, we observed a 3-fold increase in preeclampsia risk in
Hp 2-2 Hispanic women receiving vitamin C and E. The original
RCT combined vitamins C and E, an approach used in
cardiovascular disease prevention trials [47,48,49] that was
successful in small clinical trials. Therefore, we cannot determine
whether vitamin E or C alone would have been efficacious.
However, the absence of a beneficial treatment effect in women of
any Hp phenotype makes this possibility unlikely.
Second, previous studies focused primarily on Type 2 diabetics
[18,19,21,26], however women with pre-existing diabetes were
excluded from the current study. Insulin resistance increases
during pregnancy, and 3% of women in the trial developed
gestational diabetes [42]. The most extensively studied mechanism
by which vitamin E reduces cardiovascular disease risk in Type 2
diabetes is by preventing the HDL dysfunction caused by cross-
linking with glycosylated hemoglobin [28]. Hypothesizing that a
similar mechanism might be active in Type 1 diabetes, members of
our study team assessed the potential for Hp phenotype to modify
the effectiveness of vitamin C and E in preventing preeclampsia in
women with Type 1 diabetes [30]. Unfortunately, supplementa-
tion was not effective in preventing preeclampsia in women with
Type 1 diabetes of any Hp phenotype [30]. Trials in Type 2
diabetics have not been conducted.
Third, despite the similarities between preeclampsia and
cardiovascular disease, there are also critical differences. Pre-
eclampsia only occurs in pregnancy, and is proposed to result from
an interaction between materials released by the placenta, and
maternal constitutional characteristics that are largely cardiovas-
cular risk factors [40]. It may be that transient exposure to insults
in young women cannot be equated to years of chronic exposure
to cardiovascular risk factors in older women.
Conclusions
In contrast to our hypothesis, our secondary analysis of a large
RCT indicates that Hp phenotype does not influence preeclamp-
sia risk, or identify a subset of nulligravidas for whom vitamins C
and E would reduce preeclampsia risk in white, black or Hispanic
women. Vitamins C and E supplementation may increase
preeclampsia risk in Hispanic Hp 2-2 women, but due to the
limitations of secondary analysis, this finding requires verification.
Table 5. Plasma ascorbate concentrations according to Hp phenotype and prenatal/multivitamin use at randomization.
Hp Phenotype
Not Taking Prenatal/multivitamins
at Randomization
Taking Prenatal/multivitamins
at Randomization
All 8.4 (7.2, 9.5) (n = 34) 9.9 (9.4, 10.3) (n = 230)*
1-1 9.3 (7.4, 11.3) (n = 12) 9.6 (8.6, 10.5) (n = 48)
2-1 8.0 (6.3, 9.6) (n = 16) 9.8 (9.2, 10.4) (n = 126)
2-2 7.4 (4.7, 10.1) (n = 6) 10.2 (9.3, 11.1) (n = 56)
Plasma ascorbate at the pre-randomization study visit was measured in a subset of 264 patients with known Hp phenotype. The vitamin and placebo groups were
pooled, as study treatment had not yet started. Women not taking a prenatal vitamin at randomization had lower plasma ascorbate than women taking prenatal/
multivitamins at randomization (*p = 0.02). Statistical comparisons within phenotype group were not conducted due to the small number of women not taking
prenatal/multivitamins at randomization. Values are mean (95% confidence interval) in mg/L.
doi:10.1371/journal.pone.0060479.t005
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